AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30194931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy using viral vectors
Number of subjects: 0
Study 30194931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques for gene therapy
Number of subjects: 0
Study 30194931 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient selection and target zone planning
Number of subjects: 0
Study 30194931 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral vectors
Number of subjects: 0
Study 30195193 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing on vaginal self-samples
Number of subjects: 500
Study 30195193 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing on first-void urine samples
Number of subjects: 500
Study 30195193 — intervention group
Group type: COMPARATOR
Intervention: hrHPV testing on matched clinician-taken samples
Number of subjects: 500
Study 30195661 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Number of subjects: 0
Study 30195661 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring Control (SMC)
Number of subjects: 0
Study 30195661 — intervention group
Group type: EXPERIMENTAL
Intervention: BBTi and SMC
Number of subjects: 0
Study 30196791 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors
Number of subjects: 441
Study 30196853 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e9 vg/eye
Number of subjects: 9
Study 30196853 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e10 vg/eye
Number of subjects: 9
Study 30196853 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e11 vg/eye
Number of subjects: 9
Study 30196853 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector
Number of subjects: 9
Study 30197098 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide in combination with androgen deprivation therapy (ADT)
Number of subjects: 0
Study 30197098 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide in combination with ADT
Number of subjects: 0
Study 30197098 — intervention group
Group type: COMPARATOR
Intervention: Darolutamide versus placebo in addition to standard ADT and docetaxel
Number of subjects: 0
Study 30197186 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational phone call by a physician from the screening organisation
Number of subjects: 56
Study 30197186 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 56
Study 30197287 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CS) ≥ 50%
Number of subjects: 2813
Study 30197287 — intervention group
Group type: EXPERIMENTAL
Intervention: CS severity categories
Number of subjects: 2813
Study 30197287 — intervention group
Group type: EXPERIMENTAL
Intervention: CS of 90-99%
Number of subjects: 2813
Study 30197287 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded internal carotid artery
Number of subjects: 2813
Study 30197540 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly mailed self-sampling kit
Number of subjects: 9791
Study 30197540 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in self-sampling kit
Number of subjects: 9791
Study 30197540 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard second reminder for cytology screening)
Number of subjects: 9791
Study 30197625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric-induced weight loss
Number of subjects: 0
Study 30197625 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30198055 — intervention group
Group type: EXPERIMENTAL
Intervention: Premorbid traumatic brain injury (TBI)
Number of subjects: 505
Study 30198055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premorbid TBI)
Number of subjects: 505
Study 30198325 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture for 4 months
Number of subjects: 45
Study 30198934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 µg·kg(-1)
Number of subjects: 20
Study 30198934 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 30199311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 393
Study 30199311 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 393
Study 30199512 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD procedure
Number of subjects: 274
Study 30199512 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injections
Number of subjects: 274
Study 30199593 — intervention group
Group type: EXPERIMENTAL
Intervention: All-oral DAA combinations
Number of subjects: 848
Study 30200905 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) conducted by MSM, either finger prick or oral fluid, without assistance from a trained counselor
Number of subjects: 27
Study 30200905 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger prick HIV self-testing
Number of subjects: 27
Study 30200905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid HIV self-testing
Number of subjects: 27
Study 30200969 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured peer support in PMTCT (Mother Mentor study)
Number of subjects: 36
Study 30200977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound measurements in healthy volunteers
Number of subjects: 40
Study 30200977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound measurements in patients with symptomatic carotid artery stenosis
Number of subjects: 40
Study 30201016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightning strike incidents during recreational activities (hiking, hunting, timberwork)
Number of subjects: 64
Study 30201016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightning strikes occurring between June and August
Number of subjects: 64
Study 30201016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightning strikes occurring between 12:00 and 22:00 hours
Number of subjects: 64
Study 30201601 — intervention group
Group type: EXPERIMENTAL
Intervention: mSMART intervention (smartphone-based contingency management)
Number of subjects: 10
Study 30201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122) at doses ranging from 0.5-3.5 mg, 28-day continuous dosing cycles
Number of subjects: 34
Study 30201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122)
Number of subjects: 34
Study 30201821 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 850
Study 30201849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy (rituximab, high-dose pulsed steroids, cyclophosphamide until remission, followed by maintenance therapy with azathioprine)
Number of subjects: 22
Study 30201849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy
Number of subjects: 22
Study 30201848 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs)
Number of subjects: 25
Study 30202211 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (V)
Number of subjects: 72
Study 30202211 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (C)
Number of subjects: 72
Study 30202211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Valsartan and Chlorthalidone (V + C)
Number of subjects: 72
Study 30202425 — intervention group
Group type: EXPERIMENTAL
Intervention: Support services on breastfeeding during hospital stay
Number of subjects: 329
Study 30202425 — intervention group
Group type: COMPARATOR
Intervention: Higher State-Trait Anxiety Inventory score
Number of subjects: 329
Study 30202425 — intervention group
Group type: COMPARATOR
Intervention: Higher intrapartum blood loss
Number of subjects: 329
Study 30202425 — intervention group
Group type: COMPARATOR
Intervention: Occurrence of fetal anomalies
Number of subjects: 329
Study 30202425 — intervention group
Group type: COMPARATOR
Intervention: Ethnicity (Indians, Malays, other ethnicities)
Number of subjects: 329
Study 30202530 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hz high-frequency oscillation (HFO)
Number of subjects: 17
Study 30202530 — intervention group
Group type: COMPARATOR
Intervention: 7-Hz high-frequency oscillation (HFO)
Number of subjects: 17
Study 30202530 — intervention group
Group type: COMPARATOR
Intervention: lung protective conventional ventilation (CV)
Number of subjects: 17
Study 30203081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate
Number of subjects: 50
Study 30203445 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib + regorafenib + sildenafil
Number of subjects: 0
Study 30203445 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib + sildenafil
Number of subjects: 0
Study 30203580 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537
Study 30203580 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study 30204024 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound (HIFU)
Number of subjects: 27
Study 30204024 — intervention group
Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) after 12 months
Number of subjects: 27
Study 30204247 — intervention group
Group type: EXPERIMENTAL
Intervention: larotrectinib
Number of subjects: 5
Study 30204542 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk lutein concentrations (sample 1: 6.5 μg/dL, sample 2: 7.7 μg/dL)
Number of subjects: 56
Study 30204542 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk zeaxanthin concentrations (sample 1: 1.6 μg/dL, sample 2: 1.7 μg/dL)
Number of subjects: 56
Study 30204542 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant plasma lutein and zeaxanthin concentrations
Number of subjects: 56
Study 30204542 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of infant plasma lutein and zeaxanthin concentrations with milk sample 1
Number of subjects: 56
Study 30204885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) with 20 mg Fe
Number of subjects: 4011
Study 30204885 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) with 60 mg Fe + 400 µg folic acid
Number of subjects: 4011
Study 30205016 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid group
Number of subjects: 1323
Study 30205016 — intervention group
Group type: EXPERIMENTAL
Intervention: PCGs of children enrolled in Medicaid
Number of subjects: 1323
Study 30205016 — intervention group
Group type: COMPARATOR
Intervention: Baseline responses based on Medicaid status and race/ethnicity
Number of subjects: 1323
Study 30205124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-directed stereotactic body radiation therapy (mdSBRT)
Number of subjects: 37
Study 30205231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy followed by reduced-intensity conditioning (RIC) regimen
Number of subjects: 21
Study 30205314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibered platinum coil placement
Number of subjects: 56
Study 30205886 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium nitrite 25 mg (low dose)
Number of subjects: 120
Study 30205886 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sodium nitrite 60 mg (high dose)
Number of subjects: 120
Study 30205886 — intervention group
Group type: COMPARATOR
Intervention: IV sodium nitrite (both doses)
Number of subjects: 120
Study 30205939 — intervention group
Group type: EXPERIMENTAL
Intervention: MHI-13 (Mental Health Index-13)
Number of subjects: 686
Study 30205939 — intervention group
Group type: EXPERIMENTAL
Intervention: MHI-17 (Mental Health Index-17)
Number of subjects: 686
Study 30206821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 939
Study 30207748 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI), n=26
Number of subjects: 60
Study 30207748 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI) compliant group (n=15)
Number of subjects: 60
Study 30207748 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI)
Number of subjects: 60
Study 30207748 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart, n=34
Number of subjects: 60
Study 30208209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued appropriate medical therapy (CAMT)
Number of subjects: 120
Study 30208208 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term symptom subgroup (symptom duration > 60 months)
Number of subjects: 113
Study 30208208 — intervention group
Group type: COMPARATOR
Intervention: Short-term symptom subgroup (symptom duration < 12 months)
Number of subjects: 113
Study 30208208 — intervention group
Group type: COMPARATOR
Intervention: Middle-term symptom subgroup (symptom duration 12-60 months)
Number of subjects: 113
Study 30208871 — intervention group
Group type: EXPERIMENTAL
Intervention: LiverMultiScan™ multiparametric MRI
Number of subjects: 200
Study 30208971 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation (ABCR) for 10 weeks
Number of subjects: 58
Study 30208971 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 58
Study 30209124 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 717
Study 30209124 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 717
Study 30209124 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 717
Study 30209238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 149
Study 30209238 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total cholesterol
Number of subjects: 149
Study 30209556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin, and dexamethasone (GDP) combined with methotrexate (MTX) and pegaspargase (PEG-L)
Number of subjects: 65
Study 30209610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided transmural gallbladder drainage (EGBD) using lumen-apposing metal stents (LAMS)
Number of subjects: 372
Study 30209610 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic transpapillary drainage (TP)
Number of subjects: 372
Study 30209610 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous cholecystostomy tube (PTGBD)
Number of subjects: 372
Study 30210431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic management during mechanical thrombectomy
Number of subjects: 0
Study 30210431 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic management
Number of subjects: 0
Study 30210802 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based eHealth portal (McKesson, Canada, RelayHealth®)
Number of subjects: 41
Study 30211141 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Motor Intervention
Number of subjects: 0
Study 30211847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) for 12 weeks
Number of subjects: 88
Study 30211847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV) for 12 weeks
Number of subjects: 88
Study 30211847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV) for 24 weeks
Number of subjects: 88
Study 30211847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV) + Ribavirin (RBV) for 12 weeks
Number of subjects: 88
Study 30212302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-wk supervised, progressive combined exercise training program (aerobic and resistance exercise)
Number of subjects: 21
Study 30212404 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 30212404 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 30212404 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study 30212436 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node biopsy at baseline and/or after antiretroviral therapy (median 48 weeks after therapy)
Number of subjects: 67
Study 30212462 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental height test
Number of subjects: 237
Study 30212462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cormack-Lehane scale
Number of subjects: 237
Study 30212850 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs) severity in UCPPS
Number of subjects: 421
Study 30212850 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse physical well-being
Number of subjects: 421
Study 30212850 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 421
Study 30213276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) course for 8 weeks
Number of subjects: 12
Study 30213322 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SYNTAX Score (RSS) after PCI
Number of subjects: 547
Study 30213322 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally complete revascularization by FFR guidance
Number of subjects: 547
Study 30213473 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable HEPA filter air cleaner use (1-2 air cleaners in homes from early pregnancy until childbirth)
Number of subjects: 540
Study 30213473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no air cleaners)
Number of subjects: 540
Study 30213581 — intervention group
Group type: EXPERIMENTAL
Intervention: COL3A1 plasma concentration in group 3 (B1 phenotype who developed strictures)
Number of subjects: 161
Study 30213581 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP plasma concentration
Number of subjects: 161
Study 30213581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baseline concentrations of COL3A1 and anti-CSF2
Number of subjects: 161
Study 30213581 — intervention group
Group type: COMPARATOR
Intervention: COL3A1 plasma concentration
Number of subjects: 161
Study 30213611 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ)
Number of subjects: 373
Study 30213611 — intervention group
Group type: EXPERIMENTAL
Intervention: National Asthma Education and Prevention Program (NAEPP) criteria
Number of subjects: 373
Study 30213921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeonose (electronic nose)
Number of subjects: 55
Study 30214036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturia (voiding ≥3 times per night)
Number of subjects: 7343
Study 30214036 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of disturbed sleep in the model
Number of subjects: 7343
Study 30214322 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants (TTI)
Number of subjects: 103
Study 30214408 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive everolimus (Low exposure: 3-7 ng/mL)
Number of subjects: 0
Study 30214408 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive everolimus (High exposure: 9-15 ng/mL)
Number of subjects: 0
Study 30214815 — intervention group
Group type: EXPERIMENTAL
Intervention: Camden Weight Loss intervention
Number of subjects: 191
Study 30215279 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on time spent discussing weight-related behaviors and behavior change techniques used in sessions.
Number of subjects: 100
Study 30215279 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on behavior change techniques used in sessions.
Number of subjects: 100
Study 30215279 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on intervention-recommended activities implemented by parents between sessions.
Number of subjects: 100
Study 30215286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain temperature monitoring
Number of subjects: 51
Study 30215671 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation
Number of subjects: 30
Study 30215671 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET/CT scans after ART initiation
Number of subjects: 30
Study 30215671 — intervention group
Group type: EXPERIMENTAL
Intervention: Glut-1 expression of CD4+ cells and monocytes after ART initiation
Number of subjects: 30
Study 30215677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg Q4W
Number of subjects: 3817
Study 30215677 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 3 mg/kg Q2W
Number of subjects: 3817
Study 30215677 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab 240 mg Q2W
Number of subjects: 3817
Study 30216219 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-positive (≥1 CTC/7.5 mL) in high-risk patients
Number of subjects: 242
Study 30216219 — intervention group
Group type: COMPARATOR
Intervention: CTC-negative in high-risk patients
Number of subjects: 242
Study 30216219 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-positive in advanced disease
Number of subjects: 242
Study 30216219 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-positivity (univariate analysis)
Number of subjects: 242
Study 30216219 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-status (multivariable analysis)
Number of subjects: 242
Study 30216360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dys-HDL (HDL inflammatory index, HII)
Number of subjects: 88
Study 30217150 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial focused ultrasound (tFUS) to the thumb representation in M1
Number of subjects: 5
Study 30217150 — intervention group
Group type: COMPARATOR
Intervention: Sham neuromodulation
Number of subjects: 5
Study 30217223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter delivery of autologous bone marrow-derived advanced therapy medicinal product CD133
Number of subjects: 0
Study 30217227 — intervention group
Group type: EXPERIMENTAL
Intervention: TSFE using osteotomes with bone grafting
Number of subjects: 120
Study 30217227 — intervention group
Group type: EXPERIMENTAL
Intervention: TSFE using osteotomes without bone grafting
Number of subjects: 120